Why This Rare-Disease Biotech Stock Just Lost A Third Of Its Value

Amicus Therapeutics (FOLD) said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.The biotech company pitted its drug, known as AT-GAA, against Sanofi (SNY) Genzyme's Lumizyme in patients with Pompe disease. In this disorder, complex sugar called glycogen builds up in the body's cells, wreaking havoc on certain organs and tissues.
Read more...

;